EMA panel recommends Dupixent indication for urticaria in children
Source: SeekingAlpha
2026-02-27 10:49:43 ET
More on Sanofi, Regeneron Pharmaceuticals
- Why Dupixent Keeps Regeneron A Top Big Pharma Pick
- Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
- Regeneron: Expect Double-Digit Growth In 2026
- Regeneron, Sanofi win Dupixent label expansion for allergic fungal rhinosinusitis
- Regeneron granted FDA priority review for rare bone disorder therapy
Read the full article on Seeking Alpha
For further details see:
EMA panel recommends Dupixent indication for urticaria in children
Sanofi
NASDAQ: SNY
SNY Trading
-0.37% G/L:
$43.99 Last:
3,157,504 Volume:
$44.06 Open:
SNY Latest News
February 23, 2026 01:42:29 pm
Kraig Biocraft Laboratories Featured on the Cover of National Geographic
February 18, 2026 08:45:56 am
It's Not Synthetic, It's Real. Kraig Labs Nears Spider Silk Breakthrough
SNY Stock Data
$119,804,457,217
2,430,957,423
N/A
389
N/A
Pharmaceuticals
Healthcare
FR
Paris
